^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTAG2 expression

    i
    Other names: CTAG2, CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803, Cancer/testis antigen 2
    Entrez ID:
    30848
    Related biomarkers:
    Expression
    Associations

    News

    Trials
    6ms
    ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=12, Terminated, GlaxoSmithKline | Trial completion date: Dec 2025 --> Jun 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2023; The study was terminated due to a change in GSK's R&D priorities.
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
    1year
    Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=7, Terminated, GlaxoSmithKline
    New P1 trial • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3901961
    over1year
    Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P1, N=5, Terminated, GlaxoSmithKline
    New P1 trial • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097
    almost2years
    ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=67 --> 11 | Trial completion date: Feb 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
    almost2years
    ZENYTH-ESO Substudy 1 (GSK3901961), Cohort 1: a first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer (DKK 2022)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy expressing an affinity-enhanced T cell receptors (TCR) to improve recognition of cancer cells expressing NY-ESO-1 and/or LAGE-1a. This study is recruiting. This substudy will evaluate the safety and efficacy of GSK3901961 in NSCLC.
    Clinical • P1 data • P2 data • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • CTAG2 (Cancer/testis antigen 2)
    |
    CD8 expression • HLA-A*02 • CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794) • GSK3901961
    2years
    ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=67, Recruiting, GlaxoSmithKline | N=50 --> 67
    Enrollment change • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
    over2years
    ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, GlaxoSmithKline | N=38 --> 50
    Enrollment change • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
    |
    cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
    3years
    Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma (ASH 2021)
    A single lete-cel infusion was associated with antitumor activity in 6/6 heavily pretreated RRMM patients, including 1 CR, 1 VGPR, 1PR. Both responses in Arm 2 occurred prior to pembro initiation. The associated safety profile was manageable and consistent with that seen in other lete-cel studies.
    Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    PD-1 expression • CTAG2 expression
    |
    Keytruda (pembrolizumab) • letetresgene autoleucel (GSK3377794)
    over3years
    [VIRTUAL] A novel, comprehensive glimpse at NY-ESO-1 expression, mRNA to protein translation, & potential impact on clinical studies (ESMO 2021)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) are autologous T cells engineered to express a high affinity TCR capable of recognizing the HLA-A*02:01, *02:05, *02:06 and SLLMWITQC antigen complex... NY-ESO-1 & LAGE-1a were expressed in all indications investigated. NGS was highly correlated to IHC and Sanger sequencing and may be an alternative method for identifying a higher number of tumors that express biomarkers of interest. Our data show a unique platform for comprehensive assessment of disease which may improve patient stratification and management strategies.
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794)
    almost4years
    [VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (EBMT 2021)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy engineered to express a modified T cell receptor (TCR) to improve recognition of NY-ESO-1 and/or LAGE-1a expressing cancer cells. Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • CTAG2 (Cancer/testis antigen 2)
    |
    CD8 expression • CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794) • GSK3901961
    almost4years
    [VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (EBMT 2021)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy engineered to express a modified T cell receptor (TCR) to improve recognition of NY-ESO-1 and/or LAGE-1a expressing cancer cells. Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • CTAG2 (Cancer/testis antigen 2)
    |
    CD8 expression • CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794) • GSK3901961
    almost4years
    [VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (EBMT 2021)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy engineered to express a modified T cell receptor (TCR) to improve recognition of NY-ESO-1 and/or LAGE-1a expressing cancer cells. Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • CTAG2 (Cancer/testis antigen 2)
    |
    CD8 expression • CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794) • GSK3901961
    almost4years
    [VIRTUAL] CD8Α-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS (GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER PROTOCOL SUBSTUDY 1 (EBMT 2021)
    Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T cell therapy engineered to express a modified T cell receptor (TCR) to improve recognition of NY-ESO-1 and/or LAGE-1a expressing cancer cells. Exploratory endpoints include laboratory parameters, overall survival, progression-free survival, disease control rate, time to response, and anti-GSK3901961 titers. The study is currently open and recruiting.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • CTAG2 (Cancer/testis antigen 2)
    |
    CD8 expression • CTAG1B expression • CTAG2 expression
    |
    letetresgene autoleucel (GSK3377794) • GSK3901961
    almost4years
    Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1, N=10, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Aug 2020
    Clinical • Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG2 (Cancer/testis antigen 2)
    |
    EGFR mutation • ALK rearrangement • CTAG2 expression
    |
    fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    4years
    NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov)
    P1, N=3, Terminated, University of Pennsylvania | Trial completion date: Feb 2020 --> Oct 2020
    Trial completion date • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    BRAF mutation • CTAG2 expression
    |
    fludarabine IV
    over4years
    Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, GlaxoSmithKline | Trial completion date: Aug 2020 --> Dec 2021
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG2 (Cancer/testis antigen 2)
    |
    EGFR mutation • ALK rearrangement • CTAG2 expression
    |
    fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    almost5years
    Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2021 --> Aug 2020
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG2 (Cancer/testis antigen 2)
    |
    EGFR mutation • ALK rearrangement • CTAG2 expression
    |
    fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    almost5years
    NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=18 --> 3
    Enrollment closed • Enrollment change • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    BRAF mutation • CTAG2 expression
    |
    fludarabine IV
    almost5years
    Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, GlaxoSmithKline | Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Jun 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG2 (Cancer/testis antigen 2)
    |
    EGFR mutation • ALK rearrangement • CTAG2 expression
    |
    fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous